rosuvastatin

(redirected from Crestor)
Also found in: Medical.

ro·su·va·stat·in

 (rŏ-so͞o′və-stăt′n)
n.
A statin drug, C22H28FN3O6S, used in the form of its calcium salt to lower cholesterol (especially LDL) levels and to reduce the risk of heart attack and stroke in individuals with elevated risk.

[Perhaps (fluo)ro- + su(lfonyl) + -vastatin, statin suffix; see pravastatin.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

rosuvastatin

n rosuvastatina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
United Kingdom-based AstraZeneca has agreed to pay USD110m to settle Texas drugs lawsuit claims of fraudulently marketing Seroquel and Crestor, it was reported yesterday.
The trial found that use of the powerful stain rosuvastatin (Crestor) and/or the combination of the angiotensin 2 receptor blocker (ARB) candesartan plus thiazide diuretic over a six-year period did not increase the risk of erectile dysfunction (ED).
The Anglo-Swiss firm said total revenues dropped four per cent to $5.7 billion (PS4.6 billion) in the three months to September 30, as its top-selling drug took a hit from the launch of a number of Crestor generic medicines.
The Anglo-Swedish firm said total revenues dropped 4% to $5.7bn (PS4.6bn) in the three months to September 30, as its top-selling drug took a hit from the launch of a number of Crestor generic medicines.
WASHINGTON -- A federal judge has refused to issue a temporary restraining order blocking approval of new generic versions of AstraZeneca's blockbuster cholesterol drug Crestor in the United States.
Cardiovascular medicine is a key area for AstraZeneca, whose top-selling drug is the cholesterol fighter Crestor. The British-based group is working on a fixed-dose combination of Crestor and Epanova that, if successful, would extend the Crestor franchise beyond 2016, when the drug's U.S.
Crestor revenues fell 11% to $1.3 billion, Nexium dropped 1% to $940 million, Symbicort sales rose 14% to $826 million, and Synagis sales rose 5% to $404 million.
In the short term, AstraZeneca's share is expected to be driven by news around cholesterol-lowering drug Crestor and blood thinner Brilinta.
ASTRAZENECA posted better-than-expected profits yesterday as key brands such as cholesterol product Crestor helped it weather testing conditions.
Your friend was probably referring to studies that compared the effects of two statin drugs, atorvastatin (Lipitor) and rosuvastatin (Crestor), on kidney function in patients with and without diabetes.